Upcoming regulatory changes to create new opportunity for specialized offerings.
Jane F. Barlow
Advertisement
Senior Advisor to the FoCUS Project and Chief Clinical Officer for Real Endpoints
Articles by Jane F. Barlow
A follow-up survey of clinical and financial health plan leaders uncovers evolving approaches and views on the management of high-cost, curative-intended treatments with one-time administration.
A look at two surveys that reveal payer perspectives regarding current and future management of high-cost durable therapies with one-time administration.
Advertisement
Latest Updated Articles
Payer Perspectives on Reimbursement of One-Time High-Cost Durable TherapiesPublished: January 9th 2020 | Updated:
Payer Perspectives on Gene Therapy ReimbursementPublished: April 8th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
2
Could DTC Programs Help Simplify the Drug-Pricing System?
3
Pharmaceutical Executive Daily: Novo Nordisk's Shares Fall After Board Shake-Up
4
Roundup: Pharma Industry Raises Funding Aimed at Advancing the Development and Testing of Rare Disease Treatments
5
